Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Healthtrust
QuintilesIMS
US Army
Dow
McKesson
UBS
Mallinckrodt
Harvard Business School
Baxter

Generated: January 19, 2018

DrugPatentWatch Database Preview

Polidocanol - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for polidocanol and what is the scope of polidocanol freedom to operate?

Polidocanol
is the generic ingredient in two branded drugs marketed by Chemisch Fbrk Krsslr and Provensis, and is included in two NDAs. There are fifteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Polidocanol has one hundred and ninety-four patent family members in forty countries.

Two suppliers are listed for this compound.
Summary for polidocanol
Pharmacology for polidocanol
Drug ClassSclerosing Agent
Mechanism of ActionSclerosing Activity
Physiological EffectVascular Sclerosing Activity

US Patents and Regulatory Information for polidocanol

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Chemisch Fbrk Krsslr ASCLERA polidocanol SOLUTION;INTRAVENOUS 021201-002 Mar 30, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for polidocanol

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 ➤ Subscribe ➤ Subscribe
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for polidocanol

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,763,269 Therapeutic foam ➤ Subscribe
RE38919 Injectable microfoam containing a sclerosing agent ➤ Subscribe
8,048,439 Therapeutic foam ➤ Subscribe
9,545,378 Aerosol valve ➤ Subscribe
8,091,801 Generation of therapeutic microfoam ➤ Subscribe
5,676,962 Injectable microfoam containing a sclerosing agent ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for polidocanol

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
UBS
McKinsey
Chubb
Covington
US Department of Justice
Fuji
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot